ArticleAntibody therapeutics2025
Antibody-drug conjugates in cancer and beyond: progress, promise, and perspectives.
Article in Antibody therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- [Advances in Antibody-drug Conjugates for Non-small Cell Lung Cancer after Resistance to First-line Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) are transforming cancer therapy by combining antibody specificity with potent cytotoxic agents, enabling targeted tumor cell killing while minimizing systemic toxicity. This special collection of Antibody Therapeutics presents a wide overview of recent advances in ADC research and development. Topics include targeting strategies, antibody formats, innovative payloads and bispecific apoptosis triggers, formulation strategies, toxicity profiling, and conjugation technologies. Together, these contributions reflect the rapid evolution of the ADC field and point toward safer, more effective therapies for cancer and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.